ORMPNasdaqPharmaceutical PreparationsFiscal year ends December 31

ORAMED PHARMACEUTICALS INC.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 10, 2026

$4.06−0.01 (-0.25%)

Close on Oct 19, 2026

Market cap: $172.56M
P/E (TTM): 1.0
Dividend yield: 6.16%

ORAMED PHARMACEUTICALS INC. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2021 2021-08-31	FY 2020 2020-08-31	FY 2019 2019-08-31	FY 2018 2018-08-31	FY 2017 2017-08-31	FY 2016 2016-08-31	FY 2015 2015-08-31	FY 2014 2014-08-31	FY 2013 2013-08-31	FY 2012 2012-08-31	FY 2011 2011-08-31	FY 2010 2010-08-31	FY 2009 2009-08-31	FY 2008 2008-08-31
Revenue	2.00	–	1.34	2.70	2.71	2.70	2.45	2.46	0.64	–	–	–	–	–	–	–	–
Cost of Revenue	1.99	–	–	–	–	0.09	-0.09	0.19	0.49	–	–	–	–	–	–	–	–
Gross Profit	0.01	–	–	–	–	2.61	2.54	2.27	0.15	–	–	–	–	–	–	–	–
Research & Development	6.38	6.32	8.97	21	10	14	12	10	7.71	4.78	3.28	-2.27	1.68	1.16	–	–	–
General & Administrative	8.72	6.46	8.43	5.94	4.23	3.72	4.08	2.76	2.45	2.60	2.63	-2.03	1.20	1.28	–	–	–
Operating Income	-15	-13	-16	-24	-12	-15	-14	-11	-10	-7.38	-5.91	4.30	-2.88	-2.44	–	–	–
Interest Expense	–	0.85	2.04	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Interest & Investment Income	2.37	4.98	0.01	–	–	–	–	–	–	–	–	0.03	–	–	–	–	–
Other Non-Operating Income	89	-2.29	23	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Gain (Loss) on Investments	–	–	–	–	–	–	–	–	–	–	0.08	0.05	–	–	–	–	–
Pretax Income	75	-16	5.09	–	-12	-14	-13	-10	-9.63	-7.23	-5.69	4.44	-3.25	-1.59	–	–	–
Income Tax Expense	11	3.18	–	–	–	0.30	–	0.40	1.34	0.00	0.00	0.21	0.09	-0.02	–	–	–
Net Income incl. Noncontrolling Interests	64	-19	5.53	-23	-12	-14	–	–	–	–	–	–	–	–	–	–	–
Minority Interest in Earnings	-0.03	-0.04	0.44	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Net Income	64	-19	5.09	-23	-12	-14	-13	-10	-11	-7.23	-5.70	4.23	-3.34	-1.56	-2.98	-2.76	-2.77
Net Income to Common	63	-19	–	23	12	–	–	–	–	–	–	–	–	–	–	–	–
EPS (Basic)(per share)	1.53	-0.48	0.14	0.78	0.56	0.82	0.86	0.79	0.87	0.67	0.62	0.59	0.57	-0.24	–	–	–
EPS (Diluted)(per share)	1.50	-0.48	0.14	0.78	0.56	0.82	0.86	0.79	0.87	0.67	0.62	0.59	0.57	-0.24	–	–	–
Shares Outstanding (Basic, Weighted)(shares)	41	41	40	28	21	17	15	13	13	11	9.24	7.21	5.88	–	–	–	–
Shares Outstanding (Diluted, Weighted)(shares)	42	41	41	28	21	17	15	13	13	11	9.24	7.21	5.88	–	–	–	–
Dividend per Share(per share)	0.25	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
EBITDA	–	–	–	–	–	–	–	–	–	–	-5.90	4.31	-2.87	–	–	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY2025

Gross margin: 0.7%
Operating margin: -726.2%
Net margin: 8743.5%
Return on equity, FY2025: 37.0%

Financial strength

Current ratio: 4.98
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 142.1%

Valuation

P/E ratio: 1.0
Price to sales: 86.28
Price to book: –
Dividend yield: 6.16%